Medtronic Will Pay Investors $85M To End Off-Label Suit
The Minneapolis-based company said in a statement that it had reached an agreement in principle to resolve the action, subject to final documentation and court approval. Despite the settlement, Medtronic continues to deny any wrongdoing in the matter, according to the statement.
Investors first brought suit against...
To view the full article, register now.